By SPC News Staff
The FDA revised the emergency use authorization for casirivimab and imdevimab (REGEN-COV, Regeneron) to allow their use as a post-exposure prophylaxis (PEP) for COVID-19 in adults and children 12 years of age and older, weighing at least 40 kg, who are at high risk for progression to severe COVID-19, including hospitalization or death.
The monoclonal antibody cocktail, casirivimab and imdevimab, is not authorized for pre-exposure prophylaxis, according to the FDA.